Unknown

Dataset Information

0

Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis.


ABSTRACT:

Purpose

To assess disease stability (absence of intra- and/or subretinal fluid) and the portion of eyes being capable to extend their treatment interval to ≥ 12 weeks in exudative age-related macular degeneration (AMD).

Methods

A systematic literature search was performed in NCBI, PubMed, CENTRAL, and ClinicalTrials.gov to identify clinical studies reporting treatment outcomes for ranibizumab, aflibercept, and brolucizumab in exudative AMD under a treat-and-extend protocol and a follow-up of ≥ 12 months. Weighted mean differences and subgroup comparisons were used to integrate the different studies.

Results

This meta-analysis refers to 29 published series, including 27 independent samples and 5629 patients. In the pooled group, disease stability was reported in 62.9% and 56.0%, respectively, after 12 and 24 months of treatment, whereas treatment intervals were extended to ≥ 12 weeks in 37.7% and 42.6%, respectively. Ranibizumab, aflibercept, and brolucizumab differed regarding their potential to achieve disease stability (56.3%, 64.5%, and 71.5% after 12, and 50.0%, 52.7% and 75.7% after 24 months; p = < 0.001) and to allow an interval extension to ≥ 12 weeks (28.6%, 34.2%, and 53.3% after 12, and 34.2%, 47.7%, and 41.7% after 24 months; p = < 0.001).

Conclusion

The portion of eyes achieving disease stability regressed in the second year, whereas the portion of eyes under a ≥ 12-week interval increased. This discrepancy may reflect the challenges in balancing between under-treatment and a reduced treatment burden.

SUBMITTER: Garweg JG 

PROVIDER: S-EPMC8352813 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5804860 | biostudies-literature
| S-EPMC8947491 | biostudies-literature
| S-EPMC5886461 | biostudies-literature
| S-EPMC6319892 | biostudies-literature
| S-EPMC7460693 | biostudies-literature
| S-EPMC3880448 | biostudies-other
| S-EPMC3515919 | biostudies-literature
| S-EPMC8464988 | biostudies-literature
| S-EPMC4186733 | biostudies-literature
| S-EPMC8910030 | biostudies-literature